STOCK TITAN

Veru Inc - VERU STOCK NEWS

Welcome to our dedicated news page for Veru (Ticker: VERU), a resource for investors and traders seeking the latest updates and insights on Veru.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Veru's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Veru's position in the market.

Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) to host investor conference call to discuss recent financing and strategy for developing enobosarm for weight loss, along with an update on the drug pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
conferences
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) announced the pricing of an underwritten public offering of 45,833,333 shares of its common stock at $0.72 per share, expecting to raise approximately $33 million in gross proceeds. The company is focused on developing medicines for metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
-
Rhea-AI Summary
Veru Inc. (NASDAQ: VERU) has announced an underwritten public offering of shares of its common stock to fund its clinical stage drug development, including a Phase 2b clinical trial for enobosarm, an oral selective androgen receptor modulator, and for working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
Rhea-AI Summary
Veru Inc. announces plans for a Phase 2b clinical trial of enobosarm in combination with weight-loss GLP-1 drugs to prevent muscle loss and increase fat loss in overweight or obese patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Veru Inc. reaches agreement with FDA on Phase 3 clinical trial design to expand treatment population for sabizabulin in viral induced ARDS patients, potentially sufficing as a single study for NDA submission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
-
Rhea-AI Summary
Veru Inc. CEO to participate in fireside chat at Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.84%
Tags
conferences
Rhea-AI Summary
Veru Inc. announces clinical data from Phase 3 ARTEST trial of enobosarm for metastatic breast cancer. Overall response rate of 12.5% in heavily pretreated patients. Enobosarm generally well tolerated with no adverse events. Company believes data validates evaluation of enobosarm in Phase 3 ENABLAR-2 study targeting larger patient population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.94%
Tags
-
Rhea-AI Summary
Veru Inc. to present at H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.8%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Veru Inc

Nasdaq:VERU

VERU Rankings

VERU Stock Data

222.50M
112.01M
14.11%
40.25%
6.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Miami

About VERU

the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries